Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Mono Pharmacare's Enterprise Value is ₹725 Mil.
Mono Pharmacare's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was ₹50 Mil. Therefore, Mono Pharmacare's EV-to-EBIT ratio for today is 14.42.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Mono Pharmacare's Enterprise Value is ₹725 Mil.
Mono Pharmacare's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was ₹52 Mil. Therefore, Mono Pharmacare's EV-to-EBITDA ratio for today is 14.08.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Mono Pharmacare's Enterprise Value is ₹725 Mil.
Mono Pharmacare's Revenue for the trailing twelve months (TTM) ended in Sep. 2025 was ₹1,475 Mil. Therefore, Mono Pharmacare's EV-to-Revenue ratio for today is 0.49.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Mono Pharmacare (NSE:MONOPHARMA) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Mono Pharmacare's current Enterprise Value is ₹725 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Mono Pharmacare's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was ₹50 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Mono Pharmacare's current Enterprise Value is ₹725 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Mono Pharmacare's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was ₹52 Mil.
Mono Pharmacare's current Enterprise Value is ₹725 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Mono Pharmacare's Revenue for the trailing twelve months (TTM) ended in Sep. 2025 was ₹1,475 Mil.
Mono Pharmacare's current Enterprise Value is ₹725 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Mono Pharmacare's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2025 was ₹7 Mil.
Mono Pharmacare's current Enterprise Value is ₹725 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Mono Pharmacare's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 was ₹6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mono Pharmacare Enterprise Value Related Terms
Mono Pharmacare Enterprise Value Historical Data
* Premium members only.
The historical data trend for Mono Pharmacare's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mono Pharmacare Enterprise Value Competitor Comparison
For the Pharmaceutical Retailers subindustry, Mono Pharmacare's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mono Pharmacare Enterprise Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mono Pharmacare's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Mono Pharmacare's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Mono Pharmacare's Enterprise Value for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mono Pharmacare (NSE:MONOPHARMA) has a Enterprise Value of ₹725 Mil as of Jul. 14, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Mono Pharmacare and its competitors.
Is Mono Pharmacare's Enterprise Value too high?
Mono Pharmacare's current Enterprise Value is ₹725 Mil. Overall, Mono Pharmacare has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Enterprise Value compare to competitors?
Mono Pharmacare's Enterprise Value of ₹725 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Healthcare Providers & Services company?
A good Enterprise Value depends on the Healthcare Providers & Services industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Mono Pharmacare and its competitors. Mono Pharmacare's current Enterprise Value is ₹725 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Enterprise Value of ₹725 Mil. The current Enterprise Value is ₹725 Mil. Mono Pharmacare's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Enterprise Value is ₹725 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
9GF Score
Get the complete analysis for NSE:MONOPHARMA
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MONOPHARMA has been successfully added to your 
